Data continue to build the investment case for Iovance Biotherapeutics, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note after the company and investigators presented more molecular evidence highlighting the potential association with clinical response of having persistent tumor-infiltrating lymphocytes in the peripheral blood of cancer patients. Although these data showed a positive but not statistically significant trend, further investigations assessing multiple experimental time points could confirm these results in larger cohorts and reach significant stats, says the analyst. He looks forward to the clinical execution of cohort 4, as he believes this represents the "low hanging fruit to approval." Pantginis keeps a Buy rating on Iovance with a $26 price target.